$486 Million is the total value of Integral Health Asset Management, LLC's 65 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | AVALO THERAPEUTICS INC | $0 | – | -700,000 | -100.0% | -0.13% | – | |
| CMRX | Exit | CHIMERIX INC | $0 | – | -119,000 | -100.0% | -0.14% | – |
| DNLI | Exit | DENALI THERAPEUTICS INC | $0 | – | -26,000 | -100.0% | -0.22% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -30,000 | -100.0% | -0.25% | – |
| PMVP | Exit | PMV PHARMACEUTICALS INC | $0 | – | -50,000 | -100.0% | -0.27% | – |
| DTIL | Exit | PRECISION BIOSCIENCES INC | $0 | – | -350,000 | -100.0% | -0.28% | – |
| INCY | Exit | INCYTE CORP | $0 | – | -18,000 | -100.0% | -0.37% | – |
| DOCS | Exit | DOXIMITY INCcl a | $0 | – | -30,000 | -100.0% | -0.41% | – |
| ICPT | Exit | INTERCEPT PHARMACEUTICALS IN | $0 | – | -125,000 | -100.0% | -0.53% | – |
| INSP | Exit | INSPIRE MED SYS INC | $0 | – | -10,000 | -100.0% | -0.67% | – |
| TFX | Exit | TELEFLEX INCORPORATED | $0 | – | -8,000 | -100.0% | -0.74% | – |
| RGNX | Exit | REGENXBIO INC | $0 | – | -90,000 | -100.0% | -0.78% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -15,000 | -100.0% | -0.82% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -35,000 | -100.0% | -0.85% | – |
| KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -81,000 | -100.0% | -1.15% | – |
| ISRG | Exit | INTUITIVE SURGICAL INC | $0 | – | -16,000 | -100.0% | -1.26% | – |
| CI | Exit | CIGNA CORP NEW | $0 | – | -25,000 | -100.0% | -1.56% | – |
| AMED | Exit | AMEDISYS INC | $0 | – | -40,000 | -100.0% | -1.79% | – |
| ACHC | Exit | ACADIA HEALTHCARE COMPANY IN | $0 | – | -150,000 | -100.0% | -2.56% | – |
| GMED | Exit | GLOBUS MED INCcl a | $0 | – | -180,000 | -100.0% | -3.46% | – |
| PFE | Exit | PFIZER INC | $0 | – | -300,000 | -100.0% | -4.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-03
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 15 | Q3 2023 | 4.7% |
| SAGE THERAPEUTICS INC | 15 | Q2 2023 | 5.0% |
| BIOMARIN PHARMACEUTICAL INC | 15 | Q2 2023 | 4.1% |
| ENVISTA HOLDINGS CORPORATION | 14 | Q3 2023 | 4.0% |
| AKERO THERAPEUTICS INC | 14 | Q3 2023 | 1.5% |
| REVVITY INC | 13 | Q3 2023 | 4.2% |
| BLUEPRINT MEDICINES CORP | 13 | Q3 2023 | 3.3% |
| PTC THERAPEUTICS INC | 13 | Q2 2023 | 1.7% |
| ELEVANCE HEALTH INC | 12 | Q3 2023 | 6.7% |
| NEVRO CORP | 12 | Q4 2022 | 4.5% |
View Integral Health Asset Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-03 |
| 13F-HR | 2022-05-12 |
| 13F-HR | 2022-02-02 |
| 13F-HR | 2021-11-12 |
View Integral Health Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.